🔗 Share this article

Given that the United States proceeds with unprecedented adjustments to its vaccination schedules, an unexpected name appears somewhat surprisingly: Høeg, a US-based sports medicine doctor and epidemiologist who first made her name by expressing skepticism about Covid vaccines during the pandemic and has concentrated on possible deaths following COVID-19 immunization in her brief position at the US Food and Drug Administration (FDA).

Planned Shifts to Pediatric Vaccine Schedule

Public health authorities had intended to reveal radical changes to the childhood vaccination calendar earlier this month, synchronizing the US with Denmark’s national calendar, it is understood – a significant shift that would place the US at odds with many the world with little proof for improved outcomes. The planned update has been postponed until the coming year.

In place of Vinay Prasad, Dr. Høeg is listed to speak at the meeting. She was just designated interim head of the FDA’s CDER, the fifth appointee to run the center this year.

A New Direction at the Regulatory Body

Høeg's temporary position may indicate a closer partnership between the pharmaceutical and vaccine branches as Høeg and Dr. Prasad solidify control at the regulatory agency – and it signals a greater focus upon reevaluating previously authorized vaccines at the FDA.

Dr. Høeg has frequently advocated for ending certain pediatric immunization guidelines in the US in order to be more similar to Denmark, a nation with comprehensive healthcare and a citizenry approximately the population of the state of Wisconsin.

So far comments, she has continued to focus on vaccines – usually the domain of Prasad, director of the FDA’s vaccine center – instead of pharmaceutical oversight.

Doubts Over Qualifications

The appointee has no apparent experience in pharmaceutical research, regulation or administrative roles, which has been standard for former directors of the CBER. She has served at the FDA as a senior adviser to the commissioner and CBER since spring.

“It seems she lacks to have the requisite experience” for leading the CDER, remarked Dr. Jonathan Howard. “She lacks experience running a scientific study. She is not versed in running a major agency. She lacks background in pharmaceutical oversight.”

Previous directors of CBER would “understand legal statutes and the underlying principles of drug development”, commented Dr. Janet Woodcock. “Clearly, she doesn’t have the type of experience that former directors who led CBER have had.”

This division has an immense range of responsibilities at the FDA, she pointed out.

“Everybody just zeroes in on the new drug program, but the generic program clears numerous generic medications. There’s a biologic copycat branch, OTC medication office and more, and all of those must be looked after,” Dr. Woodcock explained. “The responsibility you don’t keep your eye on, that’s the thing that I always told people is going to cause problems.”

Furthermore, a substantial management aspect to the role, which supervises in excess of 5,000 staff members. “It is a massive management job, if you do it right,” she concluded.

Response and Controversial Policies

In response to questions about Dr. Høeg's credentials and whether this appointment indicates greater collaboration among FDA leaders on immunizations, a press secretary responded that the “questions stem from inaccurate assumptions”.

“Her resume matches the responsibilities of her job,” the spokesperson explained, noting the time Høeg spent counseling the FDA commissioner on “pharmaceutical safety and approval science, including computational safety modeling and shot safety tracking”.

In her interim role, Dr. Høeg takes over the commissioner’s new expedited review system, a controversial expedited medication authorization process that allegedly concerned her preceding directors. “By what process are these therapies being picked for this voucher program? Who takes the decisions?” Howard asked. “There’s a lot of secrecy happening at the agency right now.”

In general, he said, “the agency seems to be moving towards more relaxed regulations of all drugs, aside from immunizations.”

Established History on Immunizations

With vaccines, Høeg has a clearer, if problematic, past, Howard have noted. She released a study using non-validated volunteer-provided data to estimate the incidence of myocarditis following Covid immunization. She consulted for the Florida surgeon general Dr. Joseph Ladapo, who allegedly have modified findings to suggest COVID-19 vaccines are riskier than they are.

Part of her “desired changes” for the current administration encompassed altering rules for new vaccines and halting “unnecessary” vaccines, she remarked post-election on a audio program. At the agency, Dr. Høeg has allegedly proposed excluding young men from receiving Covid vaccines.

“She is an all-around ideologue who begins with her conclusions and tailors the evidence to fit the science in a very deceptive, untruthful fashion,” Dr. Howard stated.

Gaining Influence and a “Campaign of Retribution”

Høeg became part of other contrarians, {like|